Sangamo Therapeutics announces Important Derisking Milestones in Pathway to Anticipated BLA Submission for ST-920 in Fabry Disease

Click here to view

Presentation

Poster: Development of Blood-Brain Barrier Penetrant AAVs through Receptor-Targeted Capsid Engineering

Download PDF